ZURA
Zura Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZURA
Zura Bio Limited
A biotechnology company researching the clinical stage of alopecia areata and other inflammatory diseases, as well as chronic obstructive pulmonary disease and asthma
1489 W. Warm Springs Rd. #110, Henderson, NV 89014
--
Zura Bio Limited was established in January 2022. The company is a clinical-stage, multi-asset immunology company dedicated to the development of novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases with unmet needs. With the team's extensive experience, the company identifies relevant diseases and develops differentiated assets in these diseases. The company's strategic focus is to leverage the power of dual-pathway organisms to provide broader and deeper clinical benefits to patients with autoimmune and inflammatory diseases.
Company Financials
EPS
ZURA has released its 2025 Q2 earnings. EPS was reported at -0.17, versus the expected -0.3, beating expectations. The chart below visualizes how ZURA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
